Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease:a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clicnial Trial

NCT04780399 is registered in ClinicalTrials.gov with Dongzhimen Hospital, Beijing as lead sponsor.

NCT NCT04780399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04780399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease:a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clicnial Trial
Lead sponsor
Dongzhimen Hospital, Beijing
Phase
Phase 2
Overall status
Unknown status
Start date
November 9, 2021
Completion date
December 30, 2024
Enrollment
216 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, randomized, yangxue qingnao pills